Report Date: Tuesday, August 4, 2026, before market open | Call at 10:00 AM ET
Pfizer heads into its second-quarter report with shares near the lower end of their 52-week range. The stock closed July at roughly $25, "near a 52-week low of $23.40 and about 13% below its high" for the year, even as the broader market has been more resilient. Sentiment is best described as neutral-to-cautious: bears point to "tepid revenue trends, patent risks, and a mixed pipeline track record," while bulls lean on "cheap valuation, elevated dividend, and pipeline opportunities bolstered through recent M&A activity."
Consensus expectations: - Adjusted EPS: ~$0.68, down roughly 13% year-over-year - Revenue: ~$14.4 billion, down modestly (~1-2%) year-over-year - Pfizer has beaten EPS estimates in each of the trailing four quarters, including a $0.75 vs. $0.72 beat in Q1 2026
Notably, "estimates for Pfizer's 2026 earnings have declined from $2.99 to $2.96 per share over the past 30 days," suggesting some pre-print caution has crept into numbers, largely tied to COVID-franchise uncertainty and recent pipeline news.
Pfizer's Q1 2026 was solid: revenue of $14.5 billion (up 2% operationally), with underlying (ex-COVID) growth of approximately 7%, and adjusted EPS of $0.75 versus expectations. Management specifically noted it does not typically raise guidance after Q1, and reaffirmed full-year 2026 guidance of $59.5–$62.5 billion in revenue and $2.80–$3.00 in adjusted diluted EPS. That guidance has now been reaffirmed twice more since — most recently alongside the June CFO transition announcement — with no changes to the range.
A key swing factor for Q2 and the full-year guide is COVID demand. Management has been explicit that 2026 plans assume the majority of Comirnaty revenue lands in the back half of the year (vaccination season), while Paxlovid remains tied directly to infection rates, which have stayed low. As one recent preview framed it, COVID sales are "absolutely correlated with the level of infections," making this the single biggest variable behind whether guidance gets nudged up, held, or trimmed.
1. CFO Transition. On June 18, Pfizer announced that CFO Dave Denton will step down effective August 15, 2026, to pursue an opportunity outside the pharmaceutical industry — a departure the company said was unrelated to financial or operating results. Cecile Guegan, currently SVP of Finance for the Global Biopharmaceutical Business (with Pfizer since 2005), will become interim CFO effective August 16 while a permanent search is conducted. This means this call will be Denton's last as CFO, and investors will be listening closely for continuity signals on capital allocation philosophy, leverage targets, and the pace/tone of any guidance framing — especially given some analysts have flagged the leadership change itself as a source of near-term uncertainty.
2. Oncology Pipeline Setback. In late June, Pfizer's sigvotatug vedotin (SigVie-002 trial) — the first major pivotal readout from the $43 billion Seagen acquisition — missed its primary overall survival endpoint versus docetaxel in second-line non-squamous NSCLC, though a subgroup of patients on only one prior line of therapy showed a "stronger trend" of benefit. The read-through was negative for sentiment: HSBC downgraded PFE to Hold, cut its price target from $32 to $28, and lowered the drug's probability of approval to 40%, citing "a lack of short-term rerating catalysts" for the stock, partly compounding the CFO-transition overhang. The program's fate now largely rests on the ongoing first-line combination trial with Keytruda in high PD-L1 NSCLC.
3. Oncology Win. Partially offsetting that, on July 10 the FDA approved an expanded indication for Padcev (enfortumab vedotin) plus Keytruda as neoadjuvant/adjuvant treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility — the first platinum-free regimen approved across that full population, based on Phase 3 EV-304 data showing a "nearly 50% reduction in the risk of tumor recurrence, progression or death." This extends Padcev's commercial reach into earlier-stage, potentially curative-intent care and reinforces the Seagen deal's oncology commercial thesis even as sigvotatug vedotin stumbles.
4. Legal Wins Improving the Long-Term Growth Algorithm. Management has repeatedly flagged two legal developments as structurally positive: a Vyndamax (tafamidis) patent settlement that pushes loss-of-exclusivity from 2028 to mid-2031, and a favorable Belgian court ruling on EU Comirnaty supply contracts. Together, management says these give "greater confidence" in a high-single-digit five-year revenue CAGR starting in 2029, and materially improve the post-2028 cash flow outlook — a framework likely to be reiterated on this call.
Leverage ended Q1 at approximately 2.8x, which management expects to hold near current levels (or slightly higher) through the LOE transition period. Business development capacity stands at roughly $7 billion, inclusive of ~$1.65 billion in net proceeds from the closed ViiV stake sale. Management has signaled that improved cash-flow visibility (from the legal wins) puts share buybacks back into "greater consideration," though the near-term priority remains dividend preservation/growth and reinvestment in R&D and business development — CEO Albert Bourla has downplayed appetite for a "transformative" mega-merger in the near term, favoring continued tuck-ins and pipeline-focused deals (e.g., Metsera, 3SBio, YaoPharma licensing).
At roughly $25/share, PFE trades at a heavily discounted forward multiple — "at roughly 8.8 times forward earnings, well under most large-cap pharma peers" — alongside a dividend yield that has been cited as high as ~7%. The average analyst price target sits meaningfully above the current price (around $28.75), reflecting a market that has priced in a fair amount of pessimism around COVID normalization, LOE risk, and recent pipeline disappointment.
Bottom line: This is a "show me" quarter more than a pure numbers print. Consensus already bakes in a soft year-over-year comparison, so an EPS/revenue beat alone may not move the stock much. The more important signals will be (1) tone and continuity around the CFO handoff, (2) how management repositions the oncology growth narrative after the SigVie-002 miss versus the Padcev approval win, and (3) any incremental clarity on COVID seasonality that could firm up — or pressure — the full-year guide.